Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

Povorcitinib Delivers Deepening Responses Through 54 Weeks in Moderate-to-Severe HS, With Martina Porter, MD

An oral selective JAK1 inhibitor has demonstrated sustained and deepening clinical response through 54 weeks in moderate-to-severe 

, with up to 29% of patients achieving complete abscess and inflammatory nodule clearance — adding a mechanistically distinct option to a treatment landscape that has expanded rapidly but remained anchored to injectable biologics.

To discuss the findings, we spoke with Martina L. Porter, MD, of Harvard Medical School and Beth Israel Deaconess Medical Center in Boston, presenting author of the 54-week STOP-HS data at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 held in Denver, Colorado, from March 27-31. STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) are identically designed global phase 3 trials enrolling 1,227 adults total (STOP-HS1, n = 608; STOP-HS2, n = 619) with moderate-to-severe HS, randomized 1:1:1 to povorcitinib 75 mg once daily, 45 mg once daily, or placebo for a 12-week placebo-controlled period, followed by a 42-week blinded extension through week 54. Patients were required to have AN count ≥5 in ≥2 anatomic areas, Hurley stage II or III, disease duration ≥3 months, and prior systemic therapy — with 37.2% having previously received a biologic. Mean disease duration was 10.3 years (SD 9.4), mean AN count 12.0 (SD 8.8), and 75.5% had at least 1 draining tunnel at baseline.

At the primary endpoint of HiSCR50 at week 12, both doses were statistically significant versus placebo in both studies — 40.2% (45 mg) and 40.6% (75 mg) versus 29.7% placebo in STOP-HS1 (

 <.025), and 42.3% for both doses versus 28.6% placebo in STOP-HS2 (

 <.01) — with continuous improvement through week 54. By observed-cases analysis at week 54, HiSCR50 reached 60.2%–61.9% (STOP-HS1) and 57.3%–67.5% (STOP-HS2) in patients on continuous povorcitinib, with placebo crossover patients achieving comparable rates after switching at week 12. High-threshold responses deepened comparably, with up to 29.0% of patients achieving HiSCR100 at week 54. Full clearance of all inflammatory lesions (ANdT = 0) was achieved in 16.1%–20.2% of patients across both studies. Clinically meaningful improvements were observed across patient-reported outcome measures at week 54: ≥3-point decreases in skin pain NRS in 40.5%–58.0% of eligible patients, ≥4-point improvements in FATIGUE (FACIT-F) in 40.5%–49.0%, ≥4-point decreases in DLQI in 59.4%–64.7%, and ≥21-point decreases in HiSQoL total score in 33.7%–40.2%. 

Safety through week 54 was consistent with the class profile — the most common TEAEs were acne (16.4%–21.1%), nasopharyngitis (9.4%–13.6%), and upper respiratory tract infection (9.1%–12.2%). Serious TEAEs occurred in 3.7%–6.4% of patients across arms, with no malignancies excluding NMSC reported and MACE occurring in only 1 patient (0.3%) in STOP-HS2. Porter contextualized povorcitinib's JAK1 mechanism as genuinely complementary to existing options: while TNF-α and IL-17 inhibitors — including secukinumab, bimekizumab, and the phase 3-complete agents izokibep and imsidolimab — share overlapping proximity in the inflammatory signaling cascade, JAK-STAT pathway inhibition operates through a distinct mechanism that may benefit patients who have already failed biologic therapy, and Porter suggested it could potentially be considered first line pending the FDA approval pathway.

“For some patients who have already taken biologics and had very minimal response, this could be very promising for them especially. But I've also seen in clinical practice that it has a variety effects of on different types of HS patients, and so I also think it could be considered first line in the future as well, depending on how It's [potentially] approved through the FDA,” Porter said.

Relevant disclosures for Porter include Abbvie, Bristol Myers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, UCB, Trifecta Clinical, Incyte, and Anaptys Bio.

Porter ML, Martorell A, Sayed CJ, et al. Povorcitinib in patients with moderate to severe hidradenitis suppurativa: 54-week efficacy and safety results from the STOP-HS1 & STOP-HS2 phase 3 studies. Presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Presentation 80034.

Videos

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Rethinking When and How to Treat IgA Nephropathy, With Sayna Norouzi, MD

The treatment landscape for IgA nephropathy is undergoing a profound transformation, driven by updated clinical guidelines, earlier diagnosis, and a rapidly expanding therapeutic arsenal. Where management was once largely reactive, the field is now moving toward earlier, more aggressive, and more targeted intervention aimed at altering disease trajectory.

 at World Congress of Nephrology in Yokohama, Japan, Sayna Norouzi, MD, a clinical nephrologist and associate professor of medicine at Loma Linda University Medical Center, said one of the most significant shifts between the 2021 and 2025 guidelines is the redefinition of high-risk disease.

Previously, proteinuria thresholds of around 1 gram per day were used to guide treatment escalation. Now, patients with proteinuria ≥0.5 g/day are considered at risk, representing a major change in how clinicians identify and manage disease severity. This lower threshold underscores a growing recognition that IgA nephropathy is not a benign condition and can lead to kidney failure if not addressed early.

“The sooner you diagnose these patients, [the sooner] you're going to be able to treat them, and with effective treatment of IgA nephropathy, you might be able to delay dialysis or transplant or complications in general, for your patients,” she said.

The updated guidelines also emphasize more ambitious treatment goals, with a target proteinuria level ideally < 0.3 g/day. Norouzi explains that this shift reflects mounting evidence linking lower proteinuria to improved long-term outcomes, including delayed progression to dialysis or transplant. As a result, clinicians are now encouraged to pursue tighter disease control from the outset.

Another key evolution lies in treatment strategy. Historically, care began with supportive measures like blood pressure control, lifestyle modification, and initiation of RAAS blockade, with additional therapies introduced only after inadequate response. In contrast, the 2025 guidance promotes a more proactive, simultaneous approach, and while supportive care remains foundational, clinicians are now urged to initiate therapies targeting the underlying pathophysiology earlier in the disease course rather than waiting for treatment failure.

This paradigm shift is enabled by a growing list of therapeutic options. Norouzi highlights the emergence of targeted agents, including targeted-release budesonide, endothelin receptor antagonists like sparsentan and atrasentan, complement inhibitors such as iptacopan, and newer APRIL-targeting therapies. Together, these agents provide clinicians with multiple avenues to reduce proteinuria and preserve kidney function.

Despite this progress, she says important questions remain. Norouzi notes that clinical trials provide only a limited snapshot of efficacy and safety, often over relatively short durations. As these therapies enter real-world practice, she says clinicians will need to better understand long-term tolerability, optimal sequencing, and effectiveness in more heterogeneous patient populations.

“We need more data on these medications, on the safety, on how they are going to work over time. The clinical trials are looking at a limited amount of time. They follow patients for 9 months for the initial outcome data, and then they follow patients for 2 years,” Norouzi said. “Once the medication is FDA approved and it's on the market, that's when we are going to have more information and see in real life if patients are tolerating the medications. We're going to hear more about the side effects, how to monitor these patients over time, and if they are responding well to the medications as well.”

Norouzi reports relevant disclosures with Calliditas, Travere, Apellis and others.

Brooks A. KDIGO Releases Updated IgA Nephropathy, IgA Vasculitis Clinical Practice Guideline. HCPLive. September 18, 2025. Accessed March 28, 2026. 

https://www.hcplive.com/view/kdigo-releases-updated-iga-nephropathy-iga-vasculitis-clinical-practice-guideline

Campbell P. Iptacopan Receives Accelerated Approval for Reducing Proteinuria in IgA Nephropathy. August 7, 2024. Accessed April 1, 2026. 

https://www.hcplive.com/view/iptacopan-receives-accelerated-approval-for-reducing-proteinuria-in-iga-nephropathy

Campbell P. Atrasentan (Vanrafia) Receives Accelerated Approval in IgA Nephropathy. April 2, 2025. Accessed April 1, 2026. 

https://www.hcplive.com/view/atrasentan-vanrafia-receives-accelerated-approval-in-igan

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management

 has approved orforglipron (Foundayo), a once-daily oral GLP-1 RA, for chronic weight management in adults with 

 or overweight adults with ≥1 weight-related comorbidity.

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA’s decision and the myriad new treatment opportunities afforded by orforglipron’s clearance for entry into the market.

The approval of orforglipron is supported by the phase 3 ATTAIN clinical development program, which includes 2 global, randomized, double-blind, placebo-controlled trials evaluating efficacy and safety over 72 weeks.¹ The ATTAIN-1 trial enrolled 3,127 adults with obesity or overweight without diabetes, while ATTAIN-2 enrolled more than 1,600 adults with obesity or overweight and type 2 diabetes.

In ATTAIN-1, participants receiving the highest dose of orforglipron achieved a mean weight reduction of approximately 12.4% from baseline at 72 weeks among those who remained on treatment, compared with 0.9% in the placebo group. Reported average absolute weight loss was 27.3 lb versus 2.2 lb, respectively. Across all randomized participants regardless of completion status, mean weight loss was 11.1% with orforglipron compared with 2.1% with placebo.

Secondary outcomes included improvements in cardiometabolic risk markers such as waist circumference, non–high-density lipoprotein cholesterol, triglycerides, and systolic blood pressure. However, detailed peer-reviewed data from ATTAIN-1 and ATTAIN-2 remain limited at the time of reporting, and full efficacy and safety results have not yet been widely published in the medical literature.

The safety profile of orforglipron appears consistent with the GLP-1 receptor agonist class. Common adverse events include gastrointestinal symptoms such as nausea, diarrhea, constipation, vomiting, and abdominal pain. A boxed warning highlights a potential risk of thyroid C-cell tumors, based on findings observed with other GLP-1 receptor agonists in rodent studies, though human relevance remains uncertain.

The magnitude of weight loss observed with orforglipron in ATTAIN-1 appears clinically meaningful but may be modest relative to leading injectable agents. Cross-trial comparisons should be interpreted cautiously due to differences in study populations and designs. Additionally, treatment persistence rates and discontinuation due to adverse events will be important considerations in real-world use.

Ongoing and planned studies are evaluating orforglipron across additional indications, including type 2 diabetes and other cardiometabolic conditions. Future comparative trials against established GLP-1 and dual incretin therapies may help define its role in treatment algorithms.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Eli Lilly. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026. Accessed April 1, 2026. 

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

US Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026. Accessed April 1, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program

Podcasts

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD

Real-world evidence continues to refine the clinical profile of mavacamten in 

obstructive hypertrophic cardiomyopathy (HCM)

, with new data from both the MARVEL-HCM cohort and a large US Risk Evaluation and Mitigation Strategy (REMS) registry analysis reinforcing its effectiveness and safety in routine practice.

, Matthew Martinez, MD, associate professor of medicine, director of sports cardiology, and director of the Hypertrophic Cardiomyopathy program at Morristown Medical Center/Atlantic Health System, discussed the emerging data from the MARVEL-HCM trial, presented at the 

American College of Cardiology (ACC) Scientific Sessions 2026

“Most often, patients will ask, ‘How long have you been using this drug?’ So, the value of long-term safety data continues to be helpful,” Martinez told 

. “When I’m educating patients about options, I don’t determine what therapy we’re going to use. I give them the option of what’s best for them, and then we can decide together which therapeutic option is the next best step. Ongoing, long-term data continues to be helpful in that discussion.”

In MARVEL-HCM, a multicenter study of 239 patients, women presented at an older age than men (68.5 vs 59.3 years) and with more advanced disease, including higher rates of New York Heart Association (NYHA) class III symptoms and more severe diastolic dysfunction. Over 48 weeks of treatment, patients experienced significant reductions in resting and Valsalva left ventricular outflow tract (LVOT) gradients, improved functional status, and decreased severity of mitral regurgitation. Left ventricular mass index declined in both groups, supporting a role for reverse remodeling, while left ventricular ejection fraction (LVEF) remained stable, and no new safety signals were observed.

These findings are complemented by data from a large REMS-based analysis including more than 6000 patients treated with mavacamten in the United States. In this real-world cohort, 60% of patients were women and nearly two-thirds were older than 60 years, reflecting a population similar to that seen in clinical practice. Over a follow-up period of up to 22 months, reductions in LVOT obstruction were observed, with 70.3% of patients achieving a post-Valsalva gradient <30 mm Hg at 6 months.

Among more than 5,500 patients in the REMS study with monitoring data, 4.6% experienced a reduction in LVEF to <50%, and only 1.3% required hospitalization for heart failure. At the level of individual assessments, these events were infrequent, occurring in <1% of evaluations. Most patients remained on low-dose therapy, with approximately three-quarters maintained on 5 or 10 mg daily.

Taken together, these datasets highlight several clinically relevant themes. First, mavacamten demonstrates consistent effectiveness across diverse patient populations, including those with more advanced disease at baseline. Second, the drug appears to exert favorable effects on cardiac structure and hemodynamics beyond symptom relief. Third, real-world safety outcomes - particularly the low incidence of systolic dysfunction and heart failure - support the feasibility of REMS-guided monitoring in routine care.

The MARVEL-HCM findings also underscore persistent sex-based disparities in disease recognition and severity at treatment initiation. Earlier diagnosis and referral, particularly among women, may further enhance the clinical benefits observed with mavacamten in obstructive HCM.

“I think the real-world data is going to be critical,” Martinez said. “You’re already seeing the ability to be a little more granular with some of the real-world data, such as MARVEL and COLLIGO, because it allows us to ask other questions that may not have been specifically addressed during the clinical trials that led to mavacamten’s approval. All of these real-world studies allow us just a glimpse into what’s happening outside of large academic centers.”

Editors’ Note: Martinez reports disclosures with Bristol Myers Squibb, Cytokinetics, Major League Soccer, and the NHL Combine.

1: Martinez M, Wheeler M, Mehra V, et al. Real-World Evidence from the MARVEL-HCM Multicenter Study of Mavacamten – A Sex-Based Analysis of Baseline Characteristics and Cardiac Structural and Functional Changes. Abstract presented at the American College of Cardiology Scientific Sessions 2026, New Orleans, LA. March 28-30, 2026.

2: Desai MY, Seto D, Cheung M, et al. Mavacamten: Real-world experience from 22 months of the risk evaluation and mitigation strategy (REMS) program. 

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Tips on Strategies for Psoriasis in Skin of Color, With Eingun James Song, Md

Eingun James Song, MD, the director of clinical research for Frontier Dermatology, spoke in a session at the 

 titled ‘Inflammatory Skin Diseases in Skin of Color.’

 at AAD in Denver, Song noted while psoriasis is fundamentally the same immunological disease across all skin tones and ethnic groups, outcomes following treatment differ meaningfully and for reasons worth examining carefully. One challenge Song identified was diagnostic uncertainty, noting psoriasis’s presentation appearing differently on darker skin types, with some providers still being undertrained in recognizing and managing inflammatory skin diseases across different varying tones.

“I think that diagnostic uncertainty leads to a delay in care,” Song expressed.

Another issue is inequitable access, including to advanced systemic therapies and even among those who do make it to a specialist. Additionally, Song noted treatment nuances specific to these patients, including a higher risk of post-inflammatory pigmentary alteration and the impact of hair type on which topical formulations are practical to implement.

An important gap mentioned by Song, increasingly highlighted in recent publications, was underrepresentation of skin of color patients in clinical research.

 As a result of this phenomenon, clinicians cannot always confidently generalize findings from large development programs to those whose skin tones were not meaningfully reflected in such trials.

Song was also asked about artificial intelligence (AI) use and its impact on this topic. On the question of AI diagnostic tools and their well-documented limitations in darker skin tones, Song described AI as here to stay. Learning to use AI technology well rather than resist it is key, Song said, though he acknowledged current tools may not yet be fully ready for reliable use across diverse skin tones. Nevertheless, he expressed confidence in iterative improvement.

For any additional information from Song, view his full interview on-site at AAD posted above.

Song has reported serving as an investigator, consultant, and/or speaker for AbbVie, Alphyn Biologics, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, DermBiont, Galderma, Incyte, Janssen, LEO Pharma, MoonLake, Novartis, Ortho, Pfizer, Regeneron, Sanofi, Sun Pharmaceutical Industries, Timber Pharmaceuticals, and UCB.

Song E, et al. F035 Inflammatory Skin Diseases in Skin of Color. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Butera A. Dermatologic Studies Lacking in Diversity Despite Increased Efforts. HCPLive. January 26, 2022. Accessed April 1, 2026. 

https://www.hcplive.com/view/dermatologic-studies-lacking-in-diversity

Eingun James Song, MD, discusses takeaways from his AAD session on addressing concerns of patients with psoriasis and skin of color.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Tips on Strategies for Psoriasis in Skin of Color, With Eingun James Song, MD

Professor and Chair of the Department of Dermatology and Professor of Internal Medicine in the Division of Rheumatic Diseases and in the Peter O'Donnell Jr. School of Public Health at UT Southwestern Medical Center in Dallas

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

Evolving Research Landscape Drives Progress in CLE at AAD 2026

Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.

AMETHYST Phase 3 and Remaining Questions Surrounding Litifilimab in CLE

Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.

Potential of Targeting BDCA2 in Cutaneous Lupus Erythematosus Management

Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.

Navigating Multidisciplinary Care for CLE in an Evolving Landscape

Experts examine why the CLASI and CLA-IGA-R reflect the true burden of CLE.

Understanding AMETHYST Design and Patient Needs in CLE

With no targeted therapies approved in more than 70 years, new phase 2 AMETHYST data for litifilimab may signal a turning point for CLE.

Understanding Unmet Need and Recent Advances in CLE at AAD 2026 

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.

Together-PsA: Ixekizumab + Tirzepatide Deliver Superior Efficacy Over Biologic Monotherapy, With Joseph Merola, MD

Blauvelt discussed highlights from the phase 3 ONWARD1 and ONWARD2 clinical trials presented at AAD 2026.

ONWARD: Oral Envudeucitinib Demonstrates High PASI Responses in Phase 3, With Andrew Blauvelt, MD

Cheng Zhou, MD, is a professor and chair of the department of dermatology at Peking University People`s Hospital in China.

Articles

Phase 3 data on rademikibart in moderate-to-severe atopic dermatitis (AD) have been released from the AAD late-Breaking research session.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

RADIANT-AD: Rademikibart Effective Over 52 Weeks in Atopic Dermatitis, With Cheng Zhou, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These data from REMIX-1 and 2 suggest remibrutinib, in those with chronic spontaneous urticaria (CSU), can lead to fast, early symptom control.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Latest News

Povorcitinib Delivers Deepening Responses Through 54 Weeks in Moderate-to-Severe HS, With Martina Porter, MD

Rethinking When and How to Treat IgA Nephropathy, With Sayna Norouzi, MD

Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management

Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD

Tips on Strategies for Psoriasis in Skin of Color, With Eingun James Song, MD